Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04352244
Other study ID # 2009P-000101
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 5, 2020
Est. completion date March 2024

Study information

Verified date July 2023
Source Beth Israel Deaconess Medical Center
Contact Mary Elizabeth Patti, MD
Phone 6173092635
Email MaryElizabeth.Patti@joslin.harvard.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Brown fat is a type of fat, found in both children and adults, which can produce heat and regulate the body's metabolism and energy use. White fat is the more common type of fat which is used to store extra calories. Understanding more about differences between brown and white fat may allow us to develop new approaches to improve the body's metabolism.


Description:

The overarching goal of this study, is to map fat (adipose) tissue differences in humans. The investigators will probe multiple aspects of fat cell (adipocyte) identity by integrating quantitative chemical imaging, single-cell and single-nucleus RNA sequencing (sc and snRNAseq), and site-specific collection of adipocytes and adipocyte precursors. Deidentified data from these studies will be submitted to the Human Cell Atlas. The investigators anticipate that these studies will ultimately increase understanding of mechanisms by which fat (adipose) tissue regulates systemic metabolism (energy transformation in the body), and promotes risk for metabolic disease. Knowledge gained from this research may be used to set the stage for disease-specific analyses, and aid in the development of personalized medicine for metabolic diseases such as type 2 diabetes.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date March 2024
Est. primary completion date March 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion criteria: 1. Healthy participants between age 18 and 75 years undergoing planned clinically indicated procedure at BIDMC. Exclusion Criteria: 1. Body mass index (BMI) greater than or equal to 40 kg/m2 2. History of any local or systemic infectious disease with fever or requiring antibiotic within four weeks of drug administration; 3. Diabetes, either previously diagnosed or hemoglobin A1c greater than or equal to 6.5% 4. Use of oral or parenteral corticosteroids (epidural permitted) or other medication known to cause insulin resistance in the previous 6 weeks. 5. Willingness to provide informed consent and follow study procedures, including attending scheduled visits. 6. Chronic kidney disease stage 4 or 5 (including end-stage renal disease); 7. Hepatic disease, including serum alanine aminotransferase (ALT) or aspartate transaminase (AST) greater than or equal to 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as serum albumin < 3.0 g/dL; or serum bilirubin > 2.0; 8. Active malignancy (except squamous or basal cell carcinoma of skin) 9. Bleeding disorder, treatment with anticoagulants (if not discontinued prior to surgery), or platelet count <50,000; 10. Current addiction to alcohol or substances of abuse; 11. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation; 12. Use of an investigational drug within 30 days prior to screening. 13. There will be no involvement of special vulnerable populations such as fetuses, neonates, pregnant women, children, prisoners, institutionalized or incarcerated individuals, or others who may be considered vulnerable populations. 14. Because the goal is to study adult human brown adipose tissue, children are not eligible to participate.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Fat biopsy
The fat biopsy is performed during a scheduled procedure at the Beth Israel Deaconess Medical Center (BIDMC). Routine preoperative procedures will be followed, including local anesthesia (numbing a particular region of the body) or general anesthesia (being put to sleep). Adipose tissue will be sampled from different depots depending on the procedure. For example, the surgeon will collect adipose tissue from the neck and supraclavicular depots from cervical spine, thyroid, and parathyroid procedures; perinephric fat from adrenalectomies, omental fat from abdominal procedures, and paraspinal fat from lumbar spine procedures. Up to 5 pieces of fat tissue weighing about three to six grams will be removed. All other aspects of the surgical procedure will proceed as planned. Samples will be prepared for subsequent laboratory analysis.
Diagnostic Test:
Blood sampling
A blood sample will be collected in the fasting state either during preoperative testing or in the preoperative area on the day of planned procedure for measurement of adipose functional markers (leptin, adiponectin) and insulin resistance (insulin, C-peptide), and measures of glycemia (glucose, hemoglobin A1c).
Genetic:
Blood sample for DNA analysis
Targeted resequencing of DNA to identify variants associated with adipose phenotypes will be performed.

Locations

Country Name City State
United States Beth Israel Deaconess Medical Center Boston Massachusetts

Sponsors (3)

Lead Sponsor Collaborator
Beth Israel Deaconess Medical Center Chan Zuckerberg Initiative, Joslin Diabetes Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Collect human brown and white adipose tissue to prepare progenitor and differentiated cells for single nucleus RNA analysis. Adipose tissue biopsy samples will be processed for single-nucleus RNA analysis of gene expression. March 2022
Primary Collect human brown and white adipose tissue to prepare progenitor and differentiated cells for Raman spectroscopy. Adipose tissue biopsy samples will be processed for Raman spectroscopy analysis. March 2022
Primary Collect human brown and white adipose tissue to prepare cells for ex vivo differentiation Adipose tissue biopsy samples will be processed for ex vivo differentiation. March 2022
Primary Insulin resistance Insulin resistance of participants, assessed by homeostatic model of insulin resistance (HOMA-IR), will be analyzed and summarized. March 2022
Primary Hemoglobin A1c Hemoglobin A1c levels for participants will be analyzed and summarized. March 2022
Primary Fasting glucose levels Fasting glucose levels for participants will be analyzed and summarized. March 2022
Primary Body mass index (BMI) Weight and height will be combined to report BMI in kg/m^2. BMI of participants will be analyzed and summarized. March 2022
Primary Demographic characteristics Demographic characteristics of participants will be analyzed and summarized. March 2022
Secondary DNA analysis DNA will be isolated and stored from blood samples. If specific genes are differentially regulated as a function of metabolic state or anatomical location of biopsy, locus-specific or genome-wide genotyping may be performed to assess potential regulatory single-nucleotide polymorphisms (SNP). March 2022
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2